The following is a summary of the “Venous Thromboembolism in Patients Admitted for IBD: An Enterprise-Wide Experience of 86,000 Hospital Encounters,” published in the March 2023 issue of Experimental Hematology by Lightner, et al.
The purpose of this research was to examine the risk factors associated with DVT and PE in cohorts of patients with IBD who had been admitted to medical and surgical facilities and to evaluate the rate at which these complications occurred within 90 days. A look back was taken for this analysis. The research placed at a tertiary care facility for people with IBD. Patients older than 18 years old who had an inpatient hospital admission for inflammatory bowel disease (IBD) between 2002 and 2020 were included in the study.
The primary endpoints were the incidence of DVTs and PEs within 90 days after hospital admission.
Between 2002 and the beginning of 2020, 16,551 people with IBD were hospitalized. Subcutaneous heparin was administered to 35,992 patients (41.7%), and enoxaparin was administered to 8,188 patients (9.49%) to prevent venous thromboembolism during the inpatient hospital stay. The rate of deep venous thromboembolism in the 90 days following hospital admission was 4.3% (n = 3664), with 1731 patients (47%) being diagnosed during hospitalization and 1933 patients (53%) being diagnosed afterward.
The 90-day rate of pulmonary embolism was 2.4% (n = 2040) from the date of hospital admission, with 960 patients (47.2%) diagnosed on admission and 1,080 (53.6%) diagnosed after release. The study’s retrospective design and the absence of illness severity measurements acted as constraints. There was a 4.3% incidence of deep vein thromboembolism and a 2.4% incidence of pulmonary embolism among IBD patients hospitalized for at least 90 days. Most adverse outcomes (over 50%) manifested themselves after patients were sent home, and the incidence of venous thromboembolism was higher for IBD patients admitted to a medical service than those admitted to a surgical service.